Mbx Biosciences Inc (MBX)

$16.69 -0.06 (-0.36%)
Market Cap 562.70M
Revenue (ttm) 0.00
Net Income (ttm) -61.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,678,200
Avg Vol 1,300,076
Day's Range N/A - N/A
Shares Out 33.59M
Stochastic %K 5%
Beta N/A
Analysts Strong Sell
Price Target $60.28

Company Profile

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a...

Industry: Biotechnology
Sector: Healthcare
Phone: 317 659 0200
Website: mbxbio.com
Address:
11711 North Meridian Street, Suite 300, Carmel, United States
GhostOfFrankie4Fingers
GhostOfFrankie4Fingers Oct. 4 at 2:57 PM
$MBX Lol.
0 · Reply
JackSch
JackSch Oct. 2 at 9:28 PM
$MBX this director is already sitting at around 1 million loss. So yes there are dumber people than you.
0 · Reply
Paulseekerkey
Paulseekerkey Oct. 2 at 7:57 PM
$MBX Let’s go!
0 · Reply
nbkihy8
nbkihy8 Oct. 1 at 1:43 PM
$MBX Let's see, offering buyers paid $18 and director bought 12M dollars worth at $18...yeah that's a buy
1 · Reply
creativeflood
creativeflood Oct. 1 at 10:33 AM
$MBX $12 million buy from the director. Yeah, I’m still in
0 · Reply
liquidityzones
liquidityzones Sep. 30 at 10:58 PM
$MBX just now. Director bought $12M worth of shares. $50 incoming soon https://www.marketbeat.com/instant-alerts/mbx-biosciences-nysembx-director-patrick-heron-purchases-666666-shares-2025-09-30/
1 · Reply
nbkihy8
nbkihy8 Sep. 30 at 10:56 PM
$MBX This will follow a chart like $RAPP
0 · Reply
highnihilism
highnihilism Sep. 30 at 9:43 AM
$WAY Waystar: 56 trades, $61K vs $101K avg (0.61x). $53K calls / $9K puts. $MBX MBX Biosciences: 121 trades, $81K vs $262K avg (0.31x). $52K calls / $29K puts. $HBAN Huntington Bancshares: 767 trades, $67K vs $131K avg (0.51x). $52K calls / $15K puts. $ADUR Aduro Clean Tech: 113 trades, $61K vs $45K avg (1.35x). $52K calls / $9K puts.
0 · Reply
JackSch
JackSch Sep. 29 at 7:35 PM
$MBX I traded a lot of bad stocks but this one is fucking loser.
1 · Reply
IN0V8
IN0V8 Sep. 29 at 6:25 PM
$MBX Watch / Buy Jefferies raises target price to $66 from $36
1 · Reply
Latest News on MBX
MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

Sep 29, 2025, 8:00 AM EDT - 5 days ago

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Sep 25, 2025, 8:24 AM EDT - 9 days ago

Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

RIG SFIX

MBX Biosciences, Inc. - Special Call

Sep 24, 2025, 9:27 PM EDT - 10 days ago

MBX Biosciences, Inc. - Special Call

MBX Biosciences Announces Pricing of Upsized Public Offering

Sep 24, 2025, 9:15 PM EDT - 10 days ago

MBX Biosciences Announces Pricing of Upsized Public Offering

MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows Market

Sep 22, 2025, 5:10 PM EDT - 12 days ago

MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows Market

MBX Biosciences Announces Proposed Public Offering

Sep 22, 2025, 4:14 PM EDT - 12 days ago

MBX Biosciences Announces Proposed Public Offering

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

Sep 22, 2025, 7:00 AM EDT - 12 days ago

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

Sep 19, 2025, 4:18 PM EDT - 15 days ago

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

Sep 4, 2025, 8:00 AM EDT - 4 weeks ago

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

Microbix Biosystems Inc. (MBXBF) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 2:00 PM EDT - 7 weeks ago

Microbix Biosystems Inc. (MBXBF) Q2 2025 Earnings Call Transcript

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 7, 2025, 8:00 AM EDT - 2 months ago

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

Jun 23, 2025, 8:00 AM EDT - 3 months ago

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

Jun 16, 2025, 8:00 AM EDT - 3 months ago

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

Jun 10, 2025, 8:00 AM EDT - 4 months ago

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy

May 31, 2025, 7:24 AM EDT - 4 months ago

MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy

MBX Biosciences to Participate in June Investor Conferences

May 20, 2025, 8:00 AM EDT - 4 months ago

MBX Biosciences to Participate in June Investor Conferences

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 12, 2025, 8:00 AM EDT - 5 months ago

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

Apr 22, 2025, 8:00 AM EDT - 5 months ago

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 8:00 AM EDT - 6 months ago

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 17, 2025, 8:00 AM EDT - 7 months ago

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

MBX Biosciences Announces Additions to Leadership Team

Mar 5, 2025, 8:00 AM EST - 7 months ago

MBX Biosciences Announces Additions to Leadership Team

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

Mar 3, 2025, 8:00 AM EST - 7 months ago

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

MBX Biosciences to Participate in March Investor Conferences

Feb 18, 2025, 8:00 AM EST - 8 months ago

MBX Biosciences to Participate in March Investor Conferences

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

Jan 7, 2025, 7:00 AM EST - 9 months ago

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

Nov 18, 2024, 8:00 AM EST - 11 months ago

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

MBX Biosciences to Participate in Upcoming November Investor Conferences

Oct 28, 2024, 8:00 AM EDT - 1 year ago

MBX Biosciences to Participate in Upcoming November Investor Conferences

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

Sep 30, 2024, 8:00 AM EDT - 1 year ago

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 16, 2024, 4:05 PM EDT - 1 year ago

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

Sep 14, 2024, 5:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

BCAX GLXG TDTH XCH ZBIO

MBX Biosciences shares surge 44% in blockbuster Nasdaq debut

Sep 13, 2024, 12:36 PM EDT - 1 year ago

MBX Biosciences shares surge 44% in blockbuster Nasdaq debut

MBX Biosciences raises $163.2 mln in US IPO

Sep 12, 2024, 7:20 PM EDT - 1 year ago

MBX Biosciences raises $163.2 mln in US IPO

MBX Biosciences Announces Pricing of Initial Public Offering

Sep 12, 2024, 7:11 PM EDT - 1 year ago

MBX Biosciences Announces Pricing of Initial Public Offering

GhostOfFrankie4Fingers
GhostOfFrankie4Fingers Oct. 4 at 2:57 PM
$MBX Lol.
0 · Reply
JackSch
JackSch Oct. 2 at 9:28 PM
$MBX this director is already sitting at around 1 million loss. So yes there are dumber people than you.
0 · Reply
Paulseekerkey
Paulseekerkey Oct. 2 at 7:57 PM
$MBX Let’s go!
0 · Reply
nbkihy8
nbkihy8 Oct. 1 at 1:43 PM
$MBX Let's see, offering buyers paid $18 and director bought 12M dollars worth at $18...yeah that's a buy
1 · Reply
creativeflood
creativeflood Oct. 1 at 10:33 AM
$MBX $12 million buy from the director. Yeah, I’m still in
0 · Reply
liquidityzones
liquidityzones Sep. 30 at 10:58 PM
$MBX just now. Director bought $12M worth of shares. $50 incoming soon https://www.marketbeat.com/instant-alerts/mbx-biosciences-nysembx-director-patrick-heron-purchases-666666-shares-2025-09-30/
1 · Reply
nbkihy8
nbkihy8 Sep. 30 at 10:56 PM
$MBX This will follow a chart like $RAPP
0 · Reply
highnihilism
highnihilism Sep. 30 at 9:43 AM
$WAY Waystar: 56 trades, $61K vs $101K avg (0.61x). $53K calls / $9K puts. $MBX MBX Biosciences: 121 trades, $81K vs $262K avg (0.31x). $52K calls / $29K puts. $HBAN Huntington Bancshares: 767 trades, $67K vs $131K avg (0.51x). $52K calls / $15K puts. $ADUR Aduro Clean Tech: 113 trades, $61K vs $45K avg (1.35x). $52K calls / $9K puts.
0 · Reply
JackSch
JackSch Sep. 29 at 7:35 PM
$MBX I traded a lot of bad stocks but this one is fucking loser.
1 · Reply
IN0V8
IN0V8 Sep. 29 at 6:25 PM
$MBX Watch / Buy Jefferies raises target price to $66 from $36
1 · Reply
JackSch
JackSch Sep. 29 at 5:04 PM
$MBX this is a total barf
0 · Reply
creativeflood
creativeflood Sep. 29 at 2:43 PM
$MBX coiled up
0 · Reply
SweepCastApp
SweepCastApp Sep. 29 at 6:02 AM
$MBX: Unusual Options Activity Alerted PUT flow observed 153x contracts at Strike price of $20 Exp on 10/17/2025 with Premium of $55K and showing BULLISH Sentiment
0 · Reply
Tradingistheway
Tradingistheway Sep. 29 at 4:03 AM
$MBX damn 0
0 · Reply
ChartChartist
ChartChartist Sep. 27 at 5:42 PM
$ABP ngl this look great $LASE wedge here lets see 6.5 $MBX waitint $APVO checking 1.25 $PAVS getting all the eyes this weekend ; put the rocket into it monday - be ready
1 · Reply
nbkihy8
nbkihy8 Sep. 26 at 1:52 PM
$MBX Offering closing today. Now we are free to rise
1 · Reply
MTRADe_01
MTRADe_01 Sep. 26 at 12:15 PM
🚨 Squeeze Watchlist Alert 🚨 $CIPHER — ~20% short float, gaining retail heat $TERAWULF — ~40% short interest, very tight supply $NUVATION — ~28% short interest, ready to get noticed $MBX — recent 100% intraday pop on heavy volume 🔍 I’ll watch for breakout + volume + catalyst confirmation If one triggers clean, I’ll post my entry levels
0 · Reply
Bearssuckbutt
Bearssuckbutt Sep. 25 at 8:48 PM
$MBX can anybody explain to me how my puts for $17.5 10/17 still negative? i bought the when this POS was at $22 a share. i was up 40% yesterday and then negative 60% right before closing on that pump. and still not recovered BS
4 · Reply
creativeflood
creativeflood Sep. 25 at 4:39 PM
$MBX stop under lod
0 · Reply
creativeflood
creativeflood Sep. 25 at 4:06 PM
$MBX damn. Big loss here. Going to stop out soon.
0 · Reply
nbkihy8
nbkihy8 Sep. 25 at 1:51 PM
$MBX This won't stay down for long
2 · Reply
creativeflood
creativeflood Sep. 25 at 1:39 PM
$MBX I think this goes green. Everyone wants it lower but it’s holding
2 · Reply